Surrozen's President & CEO, Craig Parker, discusses how the expertise, resources and flexibility of Lonza have been fundamental in advancing its novel and complex bispecific antibody candidates that target the WNT pathway.

By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content

Latest briefing from the Knowledge Center

Sustainability webinar
Whitepaper/Executive Summary
Reducing Wastewater Incineration and Carbon Emission
As the pharmaceutical industry works to develop more sustainable processes for large-scale drug...
Video
The CDMO Value Proposition of Experience for Your Autologous Cell Therapy
bluebird bio and Lonza take the opening plenary stage at the CAR-TCR Summit to tell the story of...
Embrace molecule complexity
Whitepaper/Executive Summary
Overcome Challenges And Secure Successful Technology Transfers Of Complex Biological Products In...
A critical area to consider in selecting a CDMO is their ability to successfully complete technology...
a technician uses a machine to fill vials with a liquid substance
Article
Addressing Challenges with Clinical In-Use Testing of Biotherapeutics
The goal of in-use testing of biotherapeutics is to ensure acceptable product quality during dose...
a scientist holds a small vial up to inspect it
Article
How to Accelerate Your Biotherapeutics' Path to Clinic
Over the last few decades, many novel biotherapeutics have undergone clinical trial testing in the...
Peer-reviewed publication
Automated production of gene-modified chimeric antigen receptor T cells using the Cocoon® Platform
Abstract: Autologous cell-based therapeutics have gained increasing attention in recent years...
Article
Strategies to Optimize Expression Challenges of Multi-chain and Bispecific Antibodies
Many of today's expression platforms for recombinant protein manufacturing have been optimised for...
Webinar (on-demand)
Transfer and Development of Mammalian Processes: Effective technology transfer for mammalian derived...
Translating innovations from research laboratories to clinical and commercial manufacturing is a...
Article
Tools for Developing Successful Biologics - XS Pichia® Expression System
Lonza subject matter experts talk about the XS® Pichia Expression System and how it could benefit...
Article
Successfully Transitioning mRNA Production to cGMP Requires Early Process Engagement for Developing...
Discover why early process optimization is key to developing an efficient, cost-effective cGMP...
Technical/Service brief
XS Technologies® Microbial Platform for Protein Expression Brochure
XS Technologies® are the microbial expression systems for today’s therapeutics. While...
Presentation (on-demand)
The CDMO Value Proposition of Experience for Your Autologous Cell Therapy
As the lead partner for CAR-TCR 2023, we were thrilled to deliver the opening plenary session,...